Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study

Tempest Therapeutics

10/10/2024 14:17

** Shares of drug developer Tempest Therapeutics  TPST.O  up
19.21% at $1.60 premarket
    ** TPST to conduct a late-stage study of its experimental
drug amezalpat, in combination with Swiss drugmaker Roche's
 ROG.S  Tecentriq and bevacizumab, for the treatment of
metastatic hepatocellular carcinoma, a form of liver cancer 
    ** Under the agreement, Roche will supply Tecentriq globally
and Tempest will sponsor and lead the study
    ** Company to prepare for the start of the late-stage study
in Q1 of 2025
    ** TPST retains all development and commercial rights to
amezalpat
    ** As of last close, Tempest stock down 69.32% YTD
 

 (Reporting by Bageshri Banerjee)